| 产品详情 |
| Edit |   |
|---|
| Product Name | Farnesyltransferase Inhibitor, Cys-4-Abz-Met |
|---|
| Description | Purity ~95%. Purified by HPLC. Sequence (linear): Cys-4-Abz-Met The farnesyltransferase inhibitors (FTIs) are a class of experimental cancer drugs that target protein farnesyltransferase with the downstream effect of preventing the proper functioning of the Ras protein, which is commonly abnormally active in cancer. Studies have suggested that interference with certain post-translational modification processes seem to have quite a high selectivity for targeting cells displaying tumor phenotypes although the reason for this is a matter of controversy (as will be explained below). After translation, RAS goes through four steps of modification: isoprenylation, proteolysis, methylation and palmitoylation. Isoprenylation involves the enzyme farnesyltransferase (FTase) transferring a farnesyl group from farnesyl pyrophosphate (FPP) to the pre-RAS protein. Also, a related enzyme geranylgeranyltransferase I (GGTase I) has the ability to transfer a geranylgeranyl group to K and N-RAS (the impli |
|---|
| Size | 25mg |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | Cys-4-Abz-Met |
|---|
| Gene, Accession, CAS # | n/a |
|---|
| Catalog # | F0019-58Y |
|---|
| Price | |
|---|
| Order / More Info | Farnesyltransferase Inhibitor, Cys-4-Abz-Met from UNITED STATES BIOLOGICAL |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|